What is Stoke Therapeutics Inc (STOK) stock price today?

Stoke Therapeutics Inc (STOK) currently trades at $32.42 per share. The stock has a market capitalization of $1.92B and a P/E ratio of —x.

Is STOK stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Stoke Therapeutics Inc has a Smart Value Score of 18/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Stoke Therapeutics Inc's revenue and earnings?

Stoke Therapeutics Inc has trailing twelve-month (TTM) revenue of $184.42M with profit margins of -3.73%. Earnings per share (EPS) is $-0.12.

STOK

Stoke Therapeutics Inc

NASDAQ: STOK · HEALTHCARE · BIOTECHNOLOGY

$32.42

-2.73% today

Updated 2026-04-29

Market cap

$1.92B

P/E ratio

—

P/S ratio

10.40x

EPS (TTM)

$-0.12

Dividend yield

—

52W range

$8 – $40

Volume

0.8M

Market cap

$1.92B

P/E ratio

—

P/S ratio

10.40x

EPS (TTM)

$-0.12

Dividend yield

—

52W range

$8 – $40

Volume

0.8M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

5.3

Growth

C+

5.0

Quality

C+

2.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$45.10

+39.11%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at -3.73%

- Negative free cash flow $-30.69M

- Revenue declining -93.80% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$12.40M	$8.78M	$36.55M	$184.42M	$184.42M
Net income	$-93.11M	$-104.70M	$-88.98M	$-6.88M	$-57.93M
EPS	—	—	—	—	$-0.12
Free cash flow	$-35.83M	$-82.68M	$-87.05M	$44.91M	$-30.69M
Profit margin	-750.58%	-1,192.47%	-243.42%	-3.73%	-3.73%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
STOK	$1.92B	18	5.3	2.0	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Stoke Therapeutics Inc trades at $32.42. Our Smart Value Score of 18/100 indicates the stock is weak. TTM revenue stands at $184.42M. with profit margins at -3.73%.

Frequently asked questions

What is Stoke Therapeutics Inc's stock price?

Stoke Therapeutics Inc (STOK) trades at $32.42.

Is Stoke Therapeutics Inc overvalued?

Smart Value Score 18/100 (Grade F, Strong Sell).

What is the price target of Stoke Therapeutics Inc (STOK)?

The analyst target price is $45.10, representing +39.1% upside from the current price of $32.42.

What is Stoke Therapeutics Inc's revenue?

TTM revenue is $184.42M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio10.40x

ROE-2.37%

Beta1.22

50D MA$34.48

200D MA$28.03

Shares out0.06B

Float0.04B

Short ratio—

Avg volume0.8M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

STOK vs LLY →STOK vs JNJ →STOK vs ABBV →Stock screener →